Loading
Peroxisome Proliferator-activated Receptors · Journal article
Biomedicines · August 18, 2026
A consensus or society position rather than new primary data.
This is a consensus framework review that synthesizes evidence on zebrafish models of metabolic diseases and proposes structured criteria for model selection, phenotypic validation, and mechanistic investigation based on research objective and disease stage. The framework aims to standardize terminology, improve validation rigor, and enhance translational value, but does not itself test the framework or generate new efficacy data.
Narrative literature review with framework proposal. Zebrafish models (developmental and adult stages) of metabolic diseases; research and translational settings..
Zebrafish support in vivo imaging and high-throughput screening for studies of obesity, dyslipidemia, diabetes and complications, fatty liver disease, atherosclerosis, and inherited metabolic diseases. Zebrafish models differ in developmental stage, induction conditions, phenotypic evidence, and fidelity to human disease; a single abnormal phenotype rarely supports complete disease designation. Proposed validation framework includes morphological, biochemical, and functional assays, in vivo imaging, omics, and automated quantification for phenotypic validation.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This framework is intended to help researchers and translational scientists select appropriate zebrafish models matched to specific research questions and disease stages, and to apply consistent validation criteria that improve confidence in mechanism and drug-screening findings. It does not directly inform clinical practice but may improve the quality of preclinical evidence supporting therapeutic development.
This is a consensus framework review proposing evidence-based criteria for selecting and validating zebrafish models of metabolic disease, intended to standardize research practice and improve translational reliability.
As stated by the source record.
This framework is intended to help researchers and translational scientists select appropriate zebrafish models matched to specific research questions and disease stages, and to apply consistent validation criteria that improve confidence in mechanism and drug-screening findings. It does not directly inform clinical practice but may improve the quality of preclinical evidence supporting therapeutic development.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Metabolic diseases have diverse etiologies, prolonged courses, and multiorgan involvement, making selection of animal models matched to the research objective and disease stage essential. Zebrafish develop rapidly, are genetically tractable, and support in vivo imaging and high-throughput screening, enabling studies of obesity and dyslipidemia, diabetes and its complications, fatty liver disease, atherosclerosis, and inherited metabolic diseases. However, zebrafish models differ in developmental stage, induction conditions, phenotypic evidence, and fidelity to human disease, and a single abnormal phenotype rarely supports a complete disease designation or mechanistic conclusion. This review compares dietary, chemical, genetic, and combined models in terms of modeling characteristics, representative phenotypes, applications, and limitations. It summarizes morphological, biochemical, and functional assays, in vivo imaging, omics, and automated quantification for phenotypic validation; discusses metabolic imbalance, mitochondrial dysfunction and oxidative stress, inflammation and immunometabolism, and interorgan crosstalk; and evaluates drug-screening applications and translational limitations. We propose a model-selection framework based on research objective and disease stage, developmental stage, modeling strategy, and core-phenotype validation. Minimum validation criteria define appropriate disease terminology and inference. A larval rapid-screening-to-adult-systemic-validation strategy, multilevel outcome assessment, and cross-model validation may improve the reliability and translational value of zebrafish research on metabolic diseases.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.